Molecular imaging and the neuropathologies of parkinson’s disease

Current Topics in Behavioral Neurosciences

Volumn 11, Issue , 2011, Pages 117-148

  Cumming, Paul ^a,c   Borghammer, Per ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cerebral blood flow; CMRglc; Dopamine; Noradrenaline; Parkinson s disease; PET; Receptors; Serotonin; SPECT; TSPO

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; 6 FLUORODOPAMINE F 18; ACETYLCHOLINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CHOLINE ACETYLTRANSFERASE; DIHYDROTETRABENAZINE; DOPAMINE; IOFLUPANE I 123; NORADRENALIN; PHENYLETHANOLAMINE N METHYLTRANSFERASE; RACLOPRIDE C 11; SEROTONIN; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ALZHEIMER DISEASE; ARTICLE; AUTONOMIC DYSFUNCTION; BRAIN BLOOD FLOW; ELECTROCARDIOGRAPHY; GABAERGIC TRANSMISSION; GLUCOSE METABOLISM; HUMAN; HYPERMETABOLISM; IMMUNOCYTOCHEMISTRY; LOCUS CERULEUS; MOLECULAR IMAGING; MPTP-INDUCED PARKINSONISM; NERVE DEGENERATION; NEUROENDOCRINE SYSTEM; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXYGEN CONSUMPTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PREMOTOR CORTEX; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; SCINTIGRAPHY; ANIMAL; AUTONOMIC NERVOUS SYSTEM DISEASES; BRAIN; COMPLICATION; GLUCOSE METABOLISM DISORDERS; METABOLISM; NERVE CELL; PATHOLOGY; SCINTISCANNING; VASCULARIZATION;

ANIMALS; AUTONOMIC NERVOUS SYSTEM DISEASES; BRAIN; GLUCOSE METABOLISM DISORDERS; HUMANS; MOLECULAR IMAGING; NEURONS; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE;

EID: 84864562686     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2011_165     Document Type: Article

References (191)

1. Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 20(10): 1255-1263
2. 11C-raclopride. Arch Neurol 50(5): 474-480
3. 2-receptors. Neurology 44(7): 1325-1329
4. 11C]raclopride. Mov Disord 12(1): 33-38
5. 18F]fluorodeoxyglucose and PET. Mov Disord 13(2): 268-274
6. Araki I, Kitahara M, Oida T, Kuno S (2000) Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms. J Urol 164(5): 1640-1643
7. Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, Kaplitt MG, Feigin A, Eidelberg D (2006) Network modulation in the treatment of Parkinson's disease. Brain 129(Pt 10): 2667-2678
8. Attwell D, Laughlin SB (2001) An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 21(10): 1133-1145
9. Aubin N, Curet O, Deffois A, Carter C (1998) Aspirin and salicylate protect against MPTPinduced dopamine depletion in mice. J Neurochem 71(4): 1635-1642
10. 11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat Disord 16(1): 57-59
11. Berding G, Odin P, Brooks DJ, Nikkhah G, Matthies C, Peschel T, Shing M, Kolbe H, van Den Hoff J, Fricke H, Dengler R, Samii M, Knapp WH (2001) Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord 16(6): 1014-1022
12. Berger B, Trottier S, Gaspar P, Verney C, Alvarez C (1986) Major dopamine innervation of the cortical motor areas in the cynomolgus monkey. A radioautographic study with comparative assessment of serotonergic afferents. Neurosci Lett 72(2): 121-127
13. Bergman H, Wichmann T, Karmon B, DeLong MR (1994) The primate subthalamic nucleus II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72(2): 507-520
14. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE (1999) Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 52(3): 541-546
15. 11C]DASB. Mov Disord 23(12): 1776-1780
16. Bokobza B, Ruberg M, Scatton B, Javoy-Agid F, Agid Y (1984) [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur J Pharmacol 99(2-3): 167-175
17. Borghammer P, Jonsdottir KY, Cumming P, Ostergaard K, Vang K, Ashkanian M, Vafaee M, Iversen P, Gjedde A (2008) Normalization in PET group comparison studies-the importance of a valid reference region. Neuroimage 40(2): 529-540
18. Borghammer P, Aanerud J, Gjedde A (2009a) Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization. Neuroimage 46(4): 981-988
19. Borghammer P, Cumming P, Aanerud J, Forster S, Gjedde A (2009b) Subcortical elevation of metabolism in Parkinson's disease-a critical reappraisal in the context of global mean normalization. Neuroimage 47(4): 1514-1521
20. Borghammer P, Chakravarty M, Jonsdottir KY, Sato N, Matsuda H, Ito K, Arahata Y, Kato T, Gjedde A (2010) Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Struct Funct 214(4): 303-317
21. Borghammer P, Hansen SB, Eggers C, Chakravarty M, Vang K, Aanerud J, Hilker R, Heiss WD, Rodell A, Munk OL, Keator D, Gjedde A (2011a) Glucose metabolism in small subcortical structures in Parkinson's disease. Acta Neurologica Scandinavica. doi: 10. 1111/j. 1600-0404. 2011. 01556. x.
22. Borghammer P, Cumming P, Ostergaard K, Gjedde A, Rodell A, Bailey CJ, Vafaee MS (2011b) Cerebral oxygen metabolism in patients with early Parkinson's disease. J Neurol Sci. [Epub ahead of print]
23. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24(2): 197-211
24. Braskie MN, Wilcox CE, Landau SM, O'Neil JP, Baker SL, Madison CM, Kluth JT, Jagust WJ (2008) Relationship of striatal dopamine synthesis capacity to age and cognition. J Neurosci 28(52): 14320-14328
25. 18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol Aging 26(6): 891-898
26. 18F]fluoro-D-glucose-A85380-PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo. Clin Res Cardiol 95(2): 105-109
27. 11C]diprenorphine PET study. Brain 118(Pt 4): 951-958
28. Campos-Sousa RN, Quagliato E, da Silva BB, de Carvalho RM Jr, Ribeiro SC, de Carvalho DF (2003) Urinary symptoms in Parkinson's disease: prevalence and associated factors. Arq Neuropsiquiatr 61(2B): 359-363
29. Carlsson A, Falck B, Hillarp NA (1962) Cellular localization of brain monoamines. Acta Physiol Scand Suppl 56(196): 1-28
30. Cash R, Ruberg M, Raisman R, Agid Y (1984) Adrenergic receptors in Parkinson's disease. Brain Res 322(2): 269-275
31. Cash R, Dennis T, L'Heureux R, Raisman R, Javoy-Agid F, Scatton B (1987) Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology 37(1): 42-46
32. Chan-Palay V (1988) Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J Comp Neurol 273(4): 543-557
33. Chan-Palay V, Asan E (1989) Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 287(3): 373-392
34. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58(6): 963-967
35. Cheng AV, Ferrier IN, Morris CM, Jabeen S, Sahgal A, McKeith IG, Edwardson JA, Perry RH, Perry EK (1991) Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. J Neurol Sci 106(1): 50-55
36. Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM (1993) Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Neuroscience 54(3): 691-699
37. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15(6): 991-998
38. Cools R, Gibbs SE, Miyakawa A, Jagust W, D'Esposito M (2008) Working memory capacity predicts dopamine synthesis capacity in the human striatum. J Neurosci 28(5): 1208-1212
39. Coyle JT, Price DL, DeLong MR (1983) Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219(4589): 1184-1190
40. Cumming P, Von Krosigk M, Reiner PB, McGeer EG, Vincent SR (1986) Absence of adrenaline neurons in the guinea pig brain: a combined immunohistochemical and high-performance liquid chromatography study. Neurosci Lett 63(2): 125-130
41. Cumming P, Munk OL, Doudet D (2001) Loss of metabolites from monkey striatum during PET with FDOPA. Synapse 41(3): 212-218
42. Cumming P, Pedersen MD, Minuzzi L, Mezzomo K, Danielsen EH, Iversen P, Aagaard D, Keiding S, Munk OL, Finsen B (2006) Distribution of PK11195 binding sites in porcine brain studied by autoradiography in vitro and by positron emission tomography. Synapse 59(7): 418-426
43. Defebvre LJ, Leduc V, Duhamel A, Lecouffe P, Pasquier F, Lamy-Lhullier C, Steinling M, Destee A (1999) Technetium HMPAO SPECT study in dementia with Lewy bodies, Alzheimer's disease and idiopathic Parkinson's disease. J Nucl Med 40(6): 956-962
44. Deguchi K, Sasaki I, Tsukaguchi M, Kamoda M, Touge T, Takeuchi H, Kuriyama S (2002) Abnormalities of rate-corrected QT intervals in Parkinson's disease-a comparison with multiple system atrophy and progressive supranuclear palsy. J Neurol Sci 199(1-2): 31-37
45. Ding YS, Singhal T, Planeta-Wilson B, Gallezot JD, Nabulsi N, Labaree D, Ropchan J, Henry S, Williams W, Carson RE, Neumeister A, Malison RT (2010) PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S, S)-[(11)C] O-methylreboxetine and HRRT. Synapse 64(1): 30-38
46. Doudet DJ, Rosa-Neto P, Munk OL, Ruth TJ, Jivan S, Cumming P (2006) Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multitracer PET study. Neuroimage 30(1): 26-35
47. Dukart J, Mueller K, Horstmann A, Vogt B, Frisch S, Barthel H, Becker G, Moller HE, Villringer A, Sabri O, Schroeter ML (2010) Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage 49(2): 1490-1495
48. Eberling JL, Richardson BC, Reed BR, Wolfe N, Jagust WJ (1994) Cortical glucose metabolism in Parkinson's disease without dementia. Neurobiol Aging 15(3): 329-335
49. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S et al (1994) The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 14(5): 783-801
50. 18F]fluoro-A-85380 PET. Psychopharmacology (Berl) 202(1-3): 79-91
51. Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN (1991) Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 552(1): 113-118
52. Fernandez A, de Ceballos ML, Rose S, Jenner P, Marsden CD (1996) Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. Brain 119(Pt 3): 823-830
53. Fornai F, di Poggio AB, Pellegrini A, Ruggieri S, Paparelli A (2007) Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr Med Chem 14(22): 2330-2334
54. Fox PT, Mintun MA, Reiman EM, Raichle ME (1988) Enhanced detection of focal brain responses using intersubject averaging and change-distribution analysis of subtracted PET images. J Cereb Blood Flow Metab 8(5): 642-653
55. Frackowiak RS, Herold S, Petty RK, Morgan-Hughes JA (1988) The cerebral metabolism of glucose and oxygen measured with positron tomography in patients with mitochondrial diseases. Brain 111(Pt 5): 1009-1024
56. Frisina PG, Haroutunian V, Libow LS (2009) The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord 15(2): 144-148
57. Gai WP, Halliday GM, Blumbergs PC, Geffen LB, Blessing WW (1991) Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease. Brain 114(Pt 5): 2253-2267
58. Gai WP, Geffen LB, Denoroy L, Blessing WW (1993) Loss of C1 and C3 epinephrinesynthesizing neurons in the medulla oblongata in Parkinson's disease. Ann Neurol 33(4): 357-367
59. Gaspar P, Duyckaerts C, Alvarez C, Javoy-Agid F, Berger B (1991) Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. Ann Neurol 30(3): 365-374
60. 11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21(2): 404-412
61. Ghaemi M, Raethjen J, Hilker R, Rudolf J, Sobesky J, Deuschl G, Heiss WD (2002) Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study. Mov Disord 17(4): 782-788
62. Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST (2002) Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 58(8): 1247-1255
63. Goto S, Hirano A (1991) Catecholaminergic neurons in the parabrachial nucleus of normal individuals and patients with idiopathic Parkinson's disease. Ann Neurol 30(2): 192-196
64. 2 shows significant decreases in NET density in the human brain in Alzheimer's disease: a post-mortem autoradiographic study. Neurochem Int 56(6-7): 789-798
65. Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, Houle S, Wilson A, Mundo E, Rusjan P, Meyer J, Kish SJ (2007) Brain serotonin transporter binding in nondepressed patients with Parkinson's disease. Eur J Neurol 14(5): 523-528
66. Habeck CG (2010) Basics of multivariate analysis in neuroimaging data. J Vis Exp (41). pii. 1988. doi: 10. 3791/1988
67. Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4(11): 600-609
68. Hilker R, Voges J, Weisenbach S, Kalbe E, Burghaus L, Ghaemi M, Lehrke R, Koulousakis A, Herholz K, Sturm V, Heiss WD (2004) Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson's disease. J Cereb Blood Flow Metab 24(1): 7-16
69. 2(15)O PET study. Clin Neuropharmacol 28(1): 18-27
70. Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Labbe C, Cunningham VJ, Koepp MJ, Hammers A, Morris RG, Turjanski N, Brooks DJ (2000) Cortical dysfunction in nondemented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 123(Pt 2): 340-352
71. Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D (2007) Changes in network activity with the progression of Parkinson's disease. Brain 130(Pt 7): 1834-1846
72. Imon Y, Matsuda H, Ogawa M, Kogure D, Sunohara N (1999) SPECT image analysis using statistical parametric mapping in patients with Parkinson's disease. J Nucl Med 40(10): 1583-1589
73. Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, Satoh A, Seto M, Tsujihata M, Takahashi H (1999) Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 52(6): 1269-1271
74. 11C-yohimbine. J Nucl Med 47(12): 2008-2015
75. Javoy-Agid F, Ploska A, Agid Y (1981) Microtopography of tyrosine hydroxylase, glutamic acid decarboxylase, and choline acetyltransferase in the substantia nigra and ventral tegmental area of control and Parkinsonian brains. J Neurochem 37(5): 1218-1227
76. Jenner P, Taquet H, Mauborgne A, Benoliel JT, Cesselin F, Rose S, Javoy-Agid F, Agid Y, Marsden CD (1986) Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine treatment of the common marmoset. J Neurochem 47(5): 1548-1551
77. Jokinen P, Bruck A, Aalto S, Forsback S, Parkkola R, Rinne JO (2009) Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 15(2): 88-93
78. 11Cnicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) 188(4): 509-520
79. Kallio M, Suominen K, Haapaniemi T, Sotaniemi K, Myllyla VV, Astafiev S, Tolonen U (2004) Nocturnal cardiac autonomic regulation in Parkinson's disease. Clin Auton Res 14(2): 119-124
80. Kalpouzos G, Chetelat G, Baron JC, Landeau B, Mevel K, Godeau C, Barre L, Constans JM, Viader F, Eustache F, Desgranges B (2009) Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol Aging 30(1): 112-124
81. Kas A, Bottlaender M, Gallezot JD, Vidailhet M, Villafane G, Gregoire MC, Coulon C, Valette H, Dolle F, Ribeiro MJ, Hantraye P, Remy P (2009) Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. J Cereb Blood Flow Metab 29(9): 1601-1608
82. Kawabata K, Tachibana H (1997) Evaluation of benzodiazepine receptor in the cerebral cortex of Parkinson's disease using 123I-iomazenil SPECT. Nippon Rinsho 55(1): 244-248
83. Keeney PM, Xie J, Capaldi RA, Bennett JP Jr (2006) Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26(19): 5256-5264
84. Kitamura S, Ujike T, Kuroki S, Sakamoto S, Soeda T, Iio M, Terashi A (1988) Cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. No To Shinkei 40(10): 979-985
85. Koenigs M, Barbey AK, Postle BR, Grafman J (2009) Superior parietal cortex is critical for the manipulation of information in working memory. J Neurosci 29(47): 14980-14986
86. Koerts J, Leenders KL, Koning M, Portman AT, van Beilen M (2007) Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease. Eur J Neurosci 25(10): 3132-3136
87. Koerts J, Leenders KL, Brouwer WH (2009) Cognitive dysfunction in non-demented Parkinson's disease patients: controlled and automatic behavior. Cortex 45(8): 922-929
88. Koike Y, Takahashi A (1997) Autonomic dysfunction in Parkinson's disease. Eur Neurol 38(2): 8-12
89. Kostic VS, Lecic D, Doder M, Marinkovic J, Filipovic S (1996) Prolactin and cortisol responses to fenfluramine in Parkinson's disease. Biol Psychiatry 40(8): 769-775
90. Kumakura Y, Cumming P (2009) PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist 15(6): 635-650
91. Kumakura Y, Gjedde A, Danielsen EH, Christensen S, Cumming P (2006) Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms. J Cereb Blood Flow Metab 26(3): 358-370
92. Kumakura Y, Danielsen EH, Gjedde A, Vernaleken I, Buchholz HG, Heinz A, Grunder G, Bartenstein P, Cumming P (2010a) Elevated [(18)F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's disease. Neuroimage 49(4): 2933-2939
93. Kumakura Y, Vernaleken I, Buchholz HG, Borghammer P, Danielsen E, Grunder G, Heinz A, Bartenstein P, Cumming P (2010b) Age-dependent decline of steady state dopamine storage capacity of human brain: an FDOPA PET study. Neurobiol Aging 31(3): 447-463
94. la Fougere C, Grant S, Kostikov A, Schirrmacher R, Gravel P, Schipper H, Reader AEvans A, Thiel A (2010a) Where in vivo imaging meets cytoarchitectonics: the relationship between cortical thickness and neuronal density measured with high-resolution [(18)F]flumazenil-PET. Neuroimage 56(3): 951-960
95. 18Fdesmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med 51(4): 581-587
96. Le Jeune F, Péron J, Grandjean D, Drapier S, Haegelen C, Garin E, Millet B, Vérin M (2010) Subthalamic nucleus stimulation affects limbic and associative circuits: a PET study. Eur J Nucl Med Mol Imag 37(8): 1512-1520
97. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, Stoessl AJ (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47(4): 493-503
98. Leenders KL, Wolfson L, Gibbs JM, Wise RJ, Causon R, Jones T, Legg NJ (1985) The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. Brain 108(Pt 1): 171-191
99. Leenders KL, Perani D, Lammertsma AA, Heather JD, Buckingham P, Healy MJ, Gibbs JM, Wise RJ, Hatazawa J, Herold S et al (1990) Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. Brain 113(Pt 1): 27-47
100. Levin BE, Llabre MM, Reisman S, Weiner WJ, Sanchez-Ramos J, Singer C, Brown MC (1991) Visuospatial impairment in Parkinson's disease. Neurology 41(3): 365-369
101. Lloyd K, Hornykiewicz O (1970) Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions. Science 170(963): 1212-1213
102. Lotze M, Reimold M, Heymans U, Laihinen A, Patt M, Halsband U (2009) Reduced ventrolateral fMRI response during observation of emotional gestures related to the degree of dopaminergic impairment in Parkinson disease. J Cogn Neurosci 21(7): 1321-1331
103. Loughlin SE, Foote SL, Fallon JH (1982) Locus coeruleus projections to cortex: topography, morphology and collateralization. Brain Res Bull 9(1-6): 287-294
104. Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D (2007) Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab 27(3): 597-605
105. Makuuchi M, Kaminaga T, Sugishita M (2003) Both parietal lobes are involved in drawing: a functional MRI study and implications for constructional apraxia. Brain Res Cogn Brain Res 16(3): 338-347
106. Malessa S, Hirsch EC, Cervera P, Duyckaerts C, Agid Y (1990) Catecholaminergic systems in the medulla oblongata in parkinsonian syndromes: a quantitative immunohistochemical study in Parkinson's disease, progressive supranuclear palsy, and striatonigral degeneration. Neurology 40(11): 1739-1743
107. Maloteaux JM, Laterre EC, Laduron PM, Javoy-Agid F, Agid Y (1988a) Decrease of serotonin-S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy. Mov Disord 3(3): 255-262
108. Maloteaux JM, Luabeya MA, Vanisberg MA, Laterre EC, Laduron PM, Javoy-Agid F, Agid Y (1988b) Benzodiazepine receptors in normal human brain, in Parkinson's disease and in progressive supranuclear palsy. Brain Res 446(2): 321-332
109. Marie RM, Barre L, Rioux P, Allain P, Lechevalier B, Baron JC (1995) PET imaging of neocortical monoaminergic terminals in Parkinson's disease. J Neural Transm Park Dis Dement Sect 9(1): 55-71
110. Marie RM, Barre L, Dupuy B, Viader F, Defer G, Baron JC (1999) Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease. Neurosci Lett 260(2): 77-80
111. Mattila PM, Roytta M, Lonnberg P, Marjamaki P, Helenius H, Rinne JO (2001) Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol 102(2): 160-166
112. Mavridis M, Degryse AD, Lategan AJ, Marien MR, Colpaert FC (1991) Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41(2-3): 507-523
113. McGeer PL, Schwab C, Parent A, Doudet D (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administration. Ann Neurol 54(5): 599-604
114. Mehta MA, Sahakian BJ, McKenna PJ, Robbins TW (1999) Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease. Psychopharmacology (Berl) 146(2): 162-174
115. 2 receptor occupancy levels of acute sulpiride challenges that produce working memory and learning impairments in healthy volunteers. Psychopharmacology (Berl) 196(1): 157-165
116. Melzer TR, Watts R, Macaskill MR, Pearson JF, Rueger S, Pitcher TL, Livingston L, Graham C, Keenan R, Shankaranarayanan A, Alsop DC, Dalrymple-Alford JC, Anderson TJ (2011) Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. Brain 134(Pt 3): 845-855
117. Minoshima S, Frey KA, Foster NL, Kuhl DE (1995) Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 19(4): 541-547
118. Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander GE, Grady C, Pietrini P, Eidelberg D (1996) The metabolic topography of normal aging. J Cereb Blood Flow Metab 16(3): 385-398
119. Mohanakumar KP, Muralikrishnan D, Thomas B (2000) Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity. Brain Res 864(2): 281-290
120. 18F-dopa PET study. Neurobiol Dis 29(3): 381-390
121. Muslimovic D, Post B, Speelman JD, Schmand B (2005) Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65(8): 1239-1245
122. Nagano-Saito A, Kato T, Arahata Y, Washimi Y, Nakamura A, Abe Y, Yamada T, Iwai K, Hatano K, Kawasumi Y, Kachi T, Dagher A, Ito K (2004) Cognitive-and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies. Neuroimage 22(2): 553-561
123. Nagatsu T, Kato T, Numata Y, Ikuta K, Sano M (1977) Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain. Clin Chim Acta 75(2): 221-232
124. Nahmias C, Garnett ES, Firnau G, Lang A (1985) Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 69(3): 223-230
125. Obeso JA, Marin C, Rodriguez-Oroz C, Blesa J, Benitez-Temino B, Mena-Segovia J, Rodriguez M, Olanow CW (2008) The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol 64(2): S30-S46
126. Ohama E, Ikuta F (1976) Parkinson's disease: distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol 34(4): 311-319
127. Ohm TG, Busch C, Bohl J (1997) Unbiased estimation of neuronal numbers in the human nucleus coeruleus during aging. Neurobiol Aging 18(4): 393-399
128. Ohyama M, Senda M, Ishiwata K, Kitamura S, Mishina M, Ishii K, Toyama H, Oda K, Katayama Y (1999) Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF. Ann Nucl Med 13(5): 309-315
129. Orskov L, Jakobsen J, Dupont E, de Fine Olivarius B, Christensen NJ (1987) Autonomic function in parkinsonian patients relates to duration of disease. Neurology 37(7): 1173-1178
130. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 57(2): 168-175
131. Palner M, Kjaerby C, Knudsen GM, Cumming P (2010) Effects of unilateral 6-OHDA lesions on [(3)H]-N-propylnorapomorphine binding in striatum ex vivo and vulnerability to amphetamine-evoked dopamine release in rat. Neurochem Int 58(3): 243-247
132. Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 50(6): 743-755
133. Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ (2010) Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 133(11): 3434-3443
134. Perez-Otano I, Luquin MR, Oset C, Herrero MT, Kupsch A, Oertel W, Obeso JA, Del Rio J (1995) Neurotoxicity induced by prenatal exposure to MPTP on the monoaminergic and peptidergic systems of the marmoset brain. Exp Neurol 131(1): 108-113
135. Perry EK, Perry RH, Candy JM, Fairbairn AF, Blessed G, Dick DJ, Tomlinson BE (1984) Cortical serotonin-S2 receptor binding abnormalities in patients with Alzheimer's disease: comparisons with Parkinson's disease. Neurosci Lett 51(3): 353-357
136. Perry EK, McKeith I, Thompson P, Marshall E, Kerwin J, Jabeen S, Edwardson JA, Ince P, Blessed G, Irving D et al (1991) Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann N Y Acad Sci 640: 197-202
137. Piccini P, Weeks RA, Brooks DJ (1997) Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 42(5): 720-726
138. Pifl C, Hornykiewicz O (2006) Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys. Neurochem Int 49(5): 519-524
139. Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, Piccini P (2010) Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 75(21): 1920-1927
140. Powers WJ, Videen TO, Markham J, Black KJ, Golchin N, Perlmutter JS (2008) Cerebral mitochondrial metabolism in early Parkinson's disease. J Cereb Blood Flow Metab 28(10): 1754-1760
141. Purba JS, Hofman MA, Swaab DF (1994) Decreased number of oxytocin-immunoreactive neurons in the paraventricular nucleus of the hypothalamus in Parkinson's disease. Neurology 44(1): 84-89
142. Raffel DM, Koeppe RA, Little R, Wang CN, Liu S, Junck L, Heumann M, Gilman S (2006) PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med 47(11): 1769-1777
143. Rektorova I, Srovnalova H, Kubikova R, Prasek J (2008) Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease. Mov Disord 23(11): 1580-1587
144. Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(Pt 6): 1314-1322
145. Rodriguez-Ferreiro J, Cuetos F, Herrera E, Menendez M, Ribacoba R (2010) Cognitive impairment in Parkinson's disease without dementia. Mov Disord 25(13): 2136-2141
146. Rommelfanger KS, Weinshenker D (2007) Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem Pharmacol 74(2): 177-190
147. Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T (2001) SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. J Neurol Sci 187(1-2): 55-59
148. Sakakibara R, Odaka T, Uchiyama T, Asahina M, Yamaguchi K, Yamaguchi T, Yamanishi T, Hattori T (2003) Colonic transit time and rectoanal videomanometry in Parkinson's disease. J Neurol Neurosurg Psychiatry 74(2): 268-272
149. Saper CB, Sorrentino DM, German DC, de Lacalle S (1991) Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease. Ann Neurol 29(6): 577-584
150. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275(2): 321-328
151. Scatton B, Dennis T, L'Heureux R, Monfort JC, Duyckaerts C, Javoy-Agid F (1986) Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients. Brain Res 380(1): 181-185
152. Schenck CH, Bundlie SR, Mahowald MW (1996) Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46(2): 388-393
153. Schneider JS (1990) Chronic exposure to low doses of MPTP II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Res 534(1-2): 25-36
154. Selby G (1968) Stereotactic surgery for the relief of Parkinson's disease. 2. An analysis of the results in a series of 303 patients (413 operations). J Neurol Sci 5(2): 343-375
155. Shannak K, Rajput A, Rozdilsky B, Kish S, Gilbert J, Hornykiewicz O (1994) Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects. Brain Res 639(1): 33-41
156. 18F]fluoro-L-DOPA (FDOPA) to the ventral striatum correlates with prefrontal processing of affective stimuli. Eur J Neurosci 24(1): 305-313
157. Singaram C, Ashraf W, Gaumnitz EA, Torbey C, Sengupta A, Pfeiffer R, Quigley EM (1995) Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 346(8979): 861-864
158. Singer C, Weiner WJ, Sanchez-Ramos JR (1992) Autonomic dysfunction in men with Parkinson's disease. Eur Neurol 32(3): 134-140
159. 11C]mirtazapine binding by alpha2-adrenoceptor antagonists studied by positron emission tomography in living porcine brain. Synapse 59(8): 463-471
160. 11C]Mirtazapine binding in depressed antidepressant nonresponders studied by PET neuroimaging. Psychopharmacology (Berl) 206(1): 133-140
161. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28(5): 897-916
162. Stella F, Gobbi LT, Gobbi S, Oliani MM, Tanaka K, Pieruccini-Faria F (2007) Early impairment of cognitive functions in Parkinson's disease. Arq Neuropsiquiatr 65(2B): 406-410
163. Stiasny-Kolster K, Doerr Y, Moller JC, Hoffken H, Behr TM, Oertel WH, Mayer G (2005) Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CITSPECT. Brain 128(Pt 1): 126-137
164. Suzuki M, Kurita A, Hashimoto M, Fukumitsu N, Abo M, Ito Y, Urashima M, Inoue K (2006) Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease. J Neurol Sci 240(1-2): 15-19
165. Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N (2003) Sweating dysfunction in Parkinson's disease. Mov Disord 18(12): 1459-1463
166. Takahashi H, Kato M, Takano H, Arakawa R, Okumura M, Otsuka T, Kodaka F, Hayashi M, Okubo Y, Ito H, Suhara T (2008) Differential contributions of prefrontal and hippocampal dopamine D(1) and D(2) receptors in human cognitive functions. J Neurosci 28(46): 12032-12038
167. Takahashi S, Tohgi H, Yonezawa H, Obara S, Yamazaki E (1999) The effect of trihexyphenidyl, an anticholinergic agent, on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. J Neurol Sci 167(1): 56-61
168. Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, Dhawan V, Lesser M, Vonsattel JP, Fahn S, Eidelberg D (2010) Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 9(2): 149-158
169. Thal LJ, Sharpless NS, Hirschhorn ID, Horowitz SG, Makman MH (1983) Striatal metenkephalin concentration increases following nigrostriatal denervation. Biochem Pharmacol 32(22): 3297-3301
170. Tohgi H, Abe T, Takahashi S, Takahashi J, Hamato H (1993) Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms. Neurosci Lett 150(1): 71-74
171. Vafaee MS, Østergaard K, Sunde N, Gjedde A, Dupont E, Cumming P (2004) Focal changes of oxygen consumption in cerebral cortex of patients with Parkinson's disease during subthalamic stimulation. Neuroimage 22(2): 966-974
172. van Beilen M, Portman AT, Kiers HA, Maguire RP, Kaasinen V, Koning M, Pruim J, Leenders KL (2008) Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: a clinical and FDOPA-PET study. Parkinsonism Relat Disord 14(3): 224-228
173. Van Camp N, Boisgard R, Kuhnast B, Theze B, Viel T, Gregoire MC, Chauveau F, Boutin H, Katsifis A, Dolle F, Tavitian B (2010) In vivo imaging of neuroinflammation: a comparative study between [(18)F]PBR111, [(11)C]CLINME and [(11)C]PK11195 in an acute rodent model. Eur J Nucl Med Mol Imaging 37(5): 962-972
174. 18F]-fluoro-L-DOPA-PET investigation. Hum Brain Mapp 28(10): 931-939
175. Volpi R, Caffarra P, Scaglioni A, Maestri D, Chiodera P, Coiro V (1994) Restoration of ACTH/cortisol and LH responses to naloxone by chronic dopaminergic treatment in Parkinson's disease. J Neural Transm Park Dis Dement Sect 7(1): 1-11
176. Volpi R, Caffarra P, Boni S, Scaglioni A, Malvezzi L, Saginario A, Chiodera P, Coiro V (1997a) ACTH/cortisol involvement in the serotonergic disorder affecting the parkinsonian brain. Neuropsychobiology 35(2): 73-78
177. Volpi R, Caffarra P, Scaglioni A, Boni S, Saginario A, Chiodera P, Coiro V (1997b) Defective 5-HT 1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson's disease. Neuropsychobiology 35(2): 79-83
178. von Economo C (1931) Encephalitis lethargica. Its sequelae and treatment. (trans: Newman KO). Oxford University Press, London
179. Wakabayashi K, Takahashi H (1997) The intermediolateral nucleus and Clarke's column in Parkinson's disease. Acta Neuropathol 94(3): 287-289
180. Weder B, Azari NP, Knorr U, Seitz RJ, Keel A, Nienhusmeier M, Maguire RP, Leenders KL, Ludin HP (2000) Disturbed functional brain interactions underlying deficient tactile object discrimination in Parkinson's disease. Hum Brain Mapp 11(3): 131-145
181. Weihe E, Schutz B, Hartschuh W, Anlauf M, Schafer MK, Eiden LE (2005) Coexpression of cholinergic and noradrenergic phenotypes in human and nonhuman autonomic nervous system. J Comp Neurol 492(3): 370-379
182. Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, Duda JE, Stern MB, Mozley D, Katz IR (2005) Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med 46(2): 227-232
183. Whittington CJ, Podd J, Stewart-Williams S (2006) Memory deficits in Parkinson's disease. J Clin Exp Neuropsychol 28(5): 738-754
184. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 130(Pt 7): 1787-1798
185. Winge K, Werdelin LM, Nielsen KK, Stimpel H (2004) Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn 23(7): 689-696
186. Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H (2005) Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease. Eur J Neurol 12(11): 842-850
187. Wong KK, Muller ML, Kuwabara H, Studenski SA, Bohnen NI (2010) Olfactory loss and nigrostriatal dopaminergic denervation in the elderly. Neurosci Lett 484(3): 163-167
188. Yakushev I, Hammers A, Fellgiebel A, Schmidtmann I, Scheurich A, Buchholz HG, Peters J, Bartenstein P, Lieb K, Schreckenberger M (2009) SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging. Neuroimage 44(1): 43-50
189. Yoshita M (1998) Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 155(1): 60-67
190. Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60(3): 337-341
191. Zweig RM, Cardillo JE, Cohen M, Giere S, Hedreen JC (1993) The locus ceruleus and dementia in Parkinson's disease. Neurology 43(5): 986-991